STATISTICS IN MEDICINE, VOL. 11, 2165–2186 (1992)

SUBJECT INDEX*

Notes: Single page numbers refer to individual papers. The page ranges shown, indicate collections of papers on particular subjects. (L) after some page numbers identifies letters.

75/75 rule
  bioequivalence, 1333
Accelerated failure time model, 1871
Acquired immunodeficiency syndrome *see* **AIDS**
Adaptive rejection sampling, 1443
Adjustment methods
  attributable risk, 2083
Aggregation
  ecologic studies, 1209
  minimum sample size, 1767
Agreement
  interobserver, 101
  Kappa statistic, 1511
  subjective ranking analysis, 427–454
AIC *see* Akaike's information criterion
AIDS (Acquired immunodeficiency syndrome)
  back-calculation, 831
  doubly censored data, 1569
  dynamic model, 1425
  incidence projection, 1633
  incubation time estimation, 939
  registries, 345
  seroconversion time, parametric estimates, 591
Akaike's information criterion, 1187, 1321, 2033
Akritas test, 193
Alarms
  statistical surveillance, 1489
American Statistical Association (Biopharmaceutical Section)
  Longitudinal Data Analysis symposium, 1797–2040
Among-class variation
  cluster number estimation, 751
  cross-over trials, 727
Analysis of covariance
  repeated measures, 1685
  weighted least squares, 1843
Analysis of variance
  intraclass correlations, 1607
  repeated measures, 1033, 2111
Ancillary risk factors, 1443
ANCOVA *see* Analysis of covariance
Anderson-Darling test, 897
ANOVA *see* Analysis of variance
Anthropometry
  nutrition, 1289
Area between curves, 1289
Area under plasma concentration curve, 1333
Arrhythmias
  premature ventricular counts, 963
Arthritis
  registry, 345
Artificial nesting regression equations, 1321
Assays
  virus neutralization, 1253
Assigned share *see* Attributable risk
Association
  distribution-free estimators, 1151
Assortative mixing
  HIV epidemic dynamics, 1657
Asymmetry measures
  skewness and kurtosis, 333
Asymptotic theory
  multiple test procedures, 511
  optimal sample size determination, 547
Atherosclerosis
  carotid artery measurement, 1041
Attributable risk
  see also Relative risk; Risk
  adjusted estimators, 2083
Attrition
  patient, longitudinal data, 2029
Autocorrelation
  longitudinal data, 1929

* Compiled by Caroline Eley and Richard Raper of Indexing Specialists, 202 Church Road, Hove, BN3 2DJ, U.K.

Autoregression
see also Regression
BP tracking correlations, 1187
errors, 1929
moving average, 1409, 1929
steady state departures, 515
Average run length
statistical surveillance, 1489

Backcalculation
AIDS incidence estimation, 1633
stage-specific numbers, 831
Backward elimination, 2093
Balaam's crossover design, 1967
Balancing score
clinical trial drop-outs, 2043
Banded model
BP tracking correlations, 1187
longitudinal data, 2033
Baseline covariate models
short-term survival prediction, 1731
Baseline differences
adjustment, 1624–1626(L)
Baseline measurements
cross-over trials, 727
risk factors, 783
Bayes methods *see* Bayesian analysis; Empirical Bayes analysis; Hierarchical Bayes
Bayesian analysis
see also Empirical Bayes; Hierarchical Bayes
bioequivalence, 1777
clinical trials, 1–53, 1377
disease risk analysis, 1443
growth curve, 2001
longitudinal data, 1809, 1825, 1965–2023
meta-analysis, 141
multiple comparison, 863
prevalence estimates, 1621–1622(L)
relative risk estimation, 983
replication probability, 875
Bernoulli variables, 923
Beta blockers
myocardial infarction, 141
Beta-binomial model
correlated binomial variates, 1607
longitudinal data, 1915
Between-patient variation
non-nested regression models, 1321
Bias
bioequivalence, 1777
clinical trial drop-outs, 2043
ecologic studies, 1209
longitudinal data, 1825
omitted variables, 1195
random-digit dialling surveys, 1009
relative odds estimation, 953
repeated measures, 1685
Bibliographies
correlated categorical data, 67
Binary consensus
dichotomization rule, 317
majority rule, 317
true optimal rule, 317
two-point rule, 317
Binary data
analysis of variance, 1033
longitudinal, 1915, 1981
survival curve representation, 455
Binary response
cluster number estimation, 751
correlated categorical data, 67
cumulative sums, 1115
Binomial model
correlated variates, 1607
mark-recapture model, 1533
Binomial trials
unconditional methods, 913
Bioavailability
75/75 rule, 1333
bioequivalence, 1777
direct formulation effect, 881
dose-response relationship, 683
Biochemical data
optimal checking procedures, 1343
Bioequivalence
75/75 rule, 1333
direct formulation effect, 881
dose-response, 1777
Biopharmaceutical data
random effects models, 1809
Birth weight
maternal smoking, 643
mental development, 243
Bisection method
AIDS projections, 1425
Blood
pre-natal lead levels, 799
Blood pressure
antihypertensive drug trials, 2147
childhood, 1187
longitudinal data, 1843
tracking correlation, 1187
BMDP computer package
blood pressure tracking, 1187

discriminant analysis, 1023
follow-up data, 1195
longitudinal data, 1861, 1981, 2033
platelet transfusions, 2123
repeated measures, 115
semi-proportional hazards, 1465
short-term survival, 1731
Bonferroni inequality, 13, 37, 101, 511, 703
Book reviews
Agresti, A., *Categorcial Data Analysis*, 1791
Ahlbom, A. and Norrell, S., *Introduction to Modern Epidemiology*, 849
Cartwright, R. A., Alexander, F. E., McKinney, P. A. and Ricketts, T. J., *Leukaemia and Lymphoma. An Atlas of Distribution. . .1984–1988*, 135
Chalmers, I., Enkin, M. and Keirse, M. J. N. C. (Eds.), *Effective Care in Pregnancy and Childbirth*, 137
Desu, M. M. and Raghavarao, D., *Sample Size Methodology*, 562
Flemming, T. R. and Harrington, D. P. *Counting Processes and Survival Analysis*, 1792
Forrest, P., *Breast Cancer: The Decision to Screen*, 277
Harris, E. K. and Albert, A., *Survivorship Analysis for Clinical Studies*, 1628
Hastie, T. J. and Tibshirani, R. J., *Generalized Additive Models*, 981
Holland, W. W. and Stewart, S., *Screening in Health Care: Benefit or Bane?*, 1267
Hothorn, L. (Ed.), *Statistical Methods in Toxicology*, 1269
Leaverton, P., *A Review of Biostatistics: A Program for Self-instruction (4th edition)*, 279
Lynch, H. T. and Tautu, P. (Eds.), *Recent Progress in the Genetic Epidemiology of Cancer*, 561
Magnusson, D. and Bergman, R. (Eds.), *Data Quality in Longitudinal Research*, 1405
Manly, B. F. J., *Randomization and Monte Carlo Methods in Biology*, 136
Max, M. B., Portnoy, R. K. and Laska, E. M. (Eds.), *The Design of Analgesic Clinical Trials*, 1267
Monk, A., *Exploring Statistics with Minitab. A Workbook for the Behavioural Sciences*, 563
Olsen, J., Merletti, F., Snashall, D. and Vuylsteek, K., *Searching for Causes of Work-related Diseases. An Introduction to Epidemiology at the Work Site*, 849
Shott, S., *Statistics for Health Professionals*, 1630
Strike, P. W., *Statistical Methods in Laboratory Medicine*, 1793
Tomatis, L. (Ed.), *Cancer: Causes, Occurrence and Control*, 278
United States General Accounting Office, *Cross Design Synthesis: A New Strategy for Medical Effectiveness Research*, 1627
von Eye, A. (Ed.), *Statistical Methods in Longitudinal Research. Vol 1: Principles and Structuring Change*, 979
von Eye, A. (Ed.), *Statistical Methods in Longitudinal Research. Vol 2: Time series and Categorical Longitudinal Data*, 979
Walker, A. M., *Observation and Inference: an Introduction to the Methods of Epidemiology*, 980
Bootstrap
AIDS incidence estimation, 1633
bioavailability/bioequivalence, 881
correlated binomial variates, 1607
covariance matrix estimate, 101
gestational age estimation, 1225
missing data, 2043
model building, 2093
multiple test procedures, 511
repeated measures, 2123
residual confounding, 1747
surveillance data aberrations, 1551
Boundary estimates
closed-form estimates, 643
Box-Cox transformation, 125, 897, 1305
BP *see* Blood pressure
Breast cancer
anatomical sites risk factors, 281
cluster randomization, 307
collinearity diagnosis, 1273
crude incidence curves, 813
geographical variation, 983
large sample size monitoring, 515
prognostic factors, 281
registry, 345
Breslow-Day score statistic, 159
Brownian motion, 1391, 1477
Buckley- James procedure, 1871

Cancer
see also Breast cancer
brain tumours, 345, 2093
colon, 1759
colorectal, 1–53
correlated multiple associations, 219
laryngeal, 1747
prevalence calculation, 1579
prostate, 345, 813, 2093
registries, 345
rhabdomyosarcoma, 761
semi annual reports, 1367
toxicity grades, 2063
Cancer-diet relationship
collinearity diagnosis, 1273
Capture-recapture *see* Mark-recapture
Cardiovascular disease
plasma lipid levels, 2033
Carotid arteries
ultrasonographic measurement, 1041
Carry-over effects
cross-over trials, 715, 727
latin squares designs, 560(L)
longitudinal data, 1967
CART computer package, 475
Case influence analysis, 1615
Case load weighting
attributable risk, 2083
Case-cohort studies
see also Cohort studies
common risk ratio, 1599
Case-control studies
control sample size, 1759
data presentation, 617, 1789–1790(L)
familial aggregation, 1767
McNemar test, 1239
meta analysis, 141
optimal sample size determination, 547
polychotomous models parameterization, 557–559(L)
two-stage studies, 769
Categorical data
correlated, bibliography, 67
interobserver agreement, 101
misclassification, 271–275(L)
missing counts, 643
non-randomly missing data, 799
regression models, 67
Cause-specific curves, 813
CDF *see* Cumulative distribution functions
Censored data
bootstrap resampling, 2093
combined endpoints, 1705
cure-rate estimation, 931
group sequential trials, 1477
last case influence, 1615
longitudinal studies, 1861, 1871
mid-point imputation, 1569
paired, 193
subjective ranking, 439, 453
withdrawal, 1359
Centile curves
smoothing, 1305
Chain independence graph, 2001
Checking schedule
laboratory analyses monitoring, 1343
Chemotherapy
colorectal cancer regimens, 1–53
Children
BP tracking correlations, 1187
Chlamydial infection
transmission probability estimation, 565
Cholesterol
follow-up data, 1195
partially incomplete data, 1151
Classification
non-nested regression models, 1321
ordinal models, 131–132(L)
Clinical trials
24-hour blood pressure monitoring, 2147
Bayesian analysis, 1–53, 1377
combination drugs, 1065
combined endpoints, 1705
control sample size, 1759
cross-over trials, 715, 727
crude incidence curves, 813
drop-outs, 2043
efficacy, 1057
event probabilities, 1719
falsificationism, 1263–1265(L)
injury severity, 1171
interim analysis, 23, 37, 55
longitudinal data, 1841–1885
meta-analysis, 141, 2077
planned vs attained design, 853
randomized consent designs, 131–132(L)
registries' directory, 345
repeated measures, 1685
safety data, 1075
sample size determination, 1391
semiannual reports, 1367
serial multivariate data, 1041
stopping rules, 659, 673
study duration, 1477
subjective rankings, 427–454
toxicity grades, 2063

Clinically determined dose trials, 685
Cloning
  limited dilution, subcloning, 132–133(L)
Closed population model, 1533
Closed-form estimates
  missing counts, 643
CLUSTER FORTRAN computer program, 1915
Cluster number estimation, 751
Cluster randomization
  antecedent data, 307
  sample size requirements, 743
Cluster specific model, 67
Clustered data
  multivariate methods, 1915
  sparse, 761
CLUSTERS computer package, 603
Cochran test
  optimal sample size determination, 547
  strata-matched case-control studies, 1759
Cochran-Mantel-Haenszel statistic, 743
Coefficient of variation
  heart rate, 125
Cohen's kappa
  inference procedures, 1511
  multi-rater agreement, 101
  standard error, 1530–1532(L)
Cohort studies
  see also Case-cohort studies
  adjusted attributable risk, 2083
  disease prevalence prediction, 295
  intermediate endpoints, 167
  two-stage studies, 769
Collinearity diagnosis
  relative risk regression, 1273
Combination drugs
  clinical trial design, 1065
  positive dose-response surface, 703
Combinatorial test
  rare event clustering, 761
Combined endpoints, 1705
Common risk ratio
  case-cohort studies, 1599
Commonality
  reference centile curves, 1305
Compartmental model
  HIV epidemic, 1657
Complementary medicine
  registry, 345
Composite orthogonal polynomial repeated measures scores, 2037
Compound symmetry
  BP tracking correlations, 1187
  longitudinal data, 1843, 1915, 1967, 2033
  repeated measures, 1685
Computer packages and programs
  see also BMDP. . .; GLIM. . .; SAS. . .
  CART, 475
  CLUSTER FORTRAN, 1915
  CLUSTERS, 603
  Epi-Info, 1289
  FISHER, 2123
  GAUSS, 219, 1607, 1633
  Genstat, 1425
  LINCS, 1195
  LISP-STAT, 115, 939
  LISREL, 1195
  Minitab, 923
  NONMEM, 1777
  PROC IML, 1151
  ROC ANALYZER, 475
  Stata, 475, 897, 1115
  Statistician's Report Worksheet, 1367
Concordance correlation coefficient, 1929
Condition indices
  collinearity diagnosis, 1273
Conditional approach
  McNemar test, 1521
Conditional autoregressive plot, 983
Conditional correlation, 633
Conditional independence graphs, 2001
Conditional models
  longitudinal data, 1861, 1981
  rate of change estimation, 621
Conditional probability
  stopping rule, 659
  two-stage studies, 769
Confidence intervals
  generalized linear models, 923
  Kappa statistic, 1511
  sample sizes, 269(L)
Confidence surface, 703
Confounding
  attributable risk, 2083
  ecologic study bias, 1209
  relative odds estimation bias, 953
  residual, 1747
Consensus
  binary rules, 317
  diagnostic, 317
  subjective ranking analysis, 427–454
Constant ratio design
  sample size determination, 547
Contingency tables
  missing counts, 643
  Yates's correction, 845–847(L)

Continuity correction
  z-statistic, 913
Continuous time autoregressive models
  steady state departures, 515
Controls
  drug comparisons, 1057
CORMS *see* Composite orthogonal polynomial repeated measures scores
Coronary heart disease *see* Heart disease
Corrections to published papers, 1401, 1619
Correlated data
  binary response variables, 751
  binomial variates, 1607
  categorical, 67
  longitudinal, 1825
  relative odds estimation bias, 953
  sensitivity/specificity, 1503
  variance estimation, 1551
Correlations
  heterogenous, clustered binary data, 1915
  multiple reading procedures, 209
  unequal, repeated measures, 1685
Cost considerations
  longitudinal data, 1889
  optimal sample size determination, 547
Count crossover data
  analysis of variance, 1033
Course moderators
  dose-response relationships, 685
Cox proportional hazards model
  Bayesian analysis, 13, 37
  bootstrap resampling, 2093
  cross-validation performance, 475
  cumulative hazards functions, 1465
  differential prognostic influence, 281
  last case influence, 1615
  predictive ability comparison, 125
  residual confounding, 1747
  risk factors, 783
  survival curves, 455
Cross-sectional studies
  adjusted attributable risk, 2083
  analytical methods, 1825, 1889
  geographical coherence, 1409
Cross-validation
  mortality prediction models, 475
Crossover studies
  Balaam's design, 1967
  direct formulation effect, 881
  failure time data, 975–977(L)
  generalized estimating equations, 1033
  latin squares designs, 560(L)
  longitudinal data, 1825, 1967
  regression towards the mean, 727
  simple carry-over model, 715
Crude incidence curves, 813
Cubic spline curves, 1305
Cumulative distribution functions
  clinical trials interim analysis, 55
Cumulative hazard functions
  semi-proportional hazards, 1465
  survival curve representation, 455
Cumulative incidence
  AIDS, 591
  curves, 813
Cumulative sum
  logistic regression, 1115
  statistical surveillance, 1489
Cure-rate
  censored survival data, 931
Cusum *see* Cumulative sum

Data augmentation, 1809
Day-to-day variance
  repeated measures, 2035
de Finetti Theorem, 141
Death rate
  proportional hazards, 1103
Decay rate
  outlier detection, 2133
Decision theory
  Bayesian analysis, 5, 23, 37
  multiple comparisons, 863
  stopping rules, 659, 673
Deff *see* Design effect
Delta method
  maximum tolerated dose, 2063
  surveillance data aberrations, 1551
  transmission probability estimation, 565
Density curve
  area between curves, 1289
Dentistry
  elastase concentration, 1503
Descriptive statistics
  skewness and kurtosis, 333
Design
  combination drugs clinical trials, 1065
  planned vs. attained, 853
  two-stage studies, 769
Design effect
  Mantel-Haenszel adjustments, 603
Deterministic model
  transmission probability estimation, 565
Diabetic retinopathy
  interim analysis, 55
Diagnosis Related Groups, 1321

Diastolic blood pressure *see* Blood pressure
Dichotomous variables
  cluster number estimation, 751
Diet
  see also Nutrition
  cancer relationship, 1273
  renal disease, 1861
  variation, 533
Digit preference model, 1225
Direct formulation effect, 881
Direct substitution
  disease risk analysis, 1443
Direct treatment effect
  see also Treatment effect
  carry-over model, 715
  regression to the mean, 727
Directed acyclic graph
  relative risk estimation, 983
Directories
  clinical trials registries, 345
Discordance
  McNemar test, 1521
Discrete data
  longitudinal studies, 1825, 1981
  multiple test procedures, 511
Discrete time systems
  laboratory analyses monitoring, 1343
Discriminant analysis
  ordered variables, 1023
  risk factors, 783
Disease risk
  ancillary risk factors, 1443
  diet effects, 1273
  geographical variation, 983
Distributed models
  AIDS projections, 1425
Distribution-free estimators
  incomplete data, 1151
Dose
  escalation schemes, 2063
  maximum tolerated, 1377, 2063
  toxicity, 813
Dose-finding trial
  simple carry-over model, 715
Dose-response
  Bayesian methods, 1377
  bioequivalence, 1777
  combination drugs, 703, 1065
  experimental design, 685
Doubly censored data
  mid-point imputation, 1569
Down's syndrome
  model-based screening, 257
Drop-outs *see* Missing data
Drug exposure *see* Bioavailability
Drug users
  HIV epidemic dynamics, 1657
Drugs
  75/75 rule, 1333
  antihypertension, 2147
  bioequivalence, 1777
  combination, 1065
  dose-response relationship, 685, 703
  maximum tolerated dose, 2063
  safety data comparison, 1075
  shelf life estimation, 2001
Dynamic error component models, 533
Dynamic programming
  optimal checking procedures, 1343

EAAS *see* Electrothermal atomic ...
Early termination
  see also Stopping rules
  study duration, 1477
ECGs *see* Electrocardiograms
ECM *see* Expected-Conditional Maximization
Ecologic studies
  biases, 1209
Ederer-Myers-Mantel test, 761
Effect modification
  attributable risk, 2083
  ecologic study bias, 1209
Efficacy
  AIDS incidence, 1633
  drug trials, 1057
  platelet transfusions, 2123
Electrocardiograms
  premature ventricular counts, 963
Electrothermal atomic absorption
    spectrophotometry, 1343
EM *see* Expectation-Maximization
Empirical Bayes
  correlated multiple associations, 219
  longitudinal data, 1965–2023
  rate of change estimation, 621
  relative risk estimation, 983
Empirical semi-variogram plot
  repeated measures, 2111
Endocrinology
  outlier detection methods, 2133
Endpoints
  clinical trials, 1705
  intermediate/surrogate, 167
Energy intake
  between and within subject variation, 533
Epi-Info computer package, 1289

Epidemiology
AIDS incidence projection, 1633
collinearity diagnosis, 1273
disease risk analysis, 1443
ecologic studies, 1209
familial aggregation, 1767
geographical coherence, 1409
HIV epidemic dynamics, 1657
mark-recapture model, 1533
measles incubation period, 579
omitted variable bias, 1195
prevalence estimation, 1579, 1591
public health surveillance, 1551
rare event clustering, 761
relative odds estimation bias, 953
relative risk estimation, 983
residual confounding, 1747
risk factor/disease incidence, 783
Erlangian distribution, 831
Error
generalized t and rank-sum statistics, 491–509
measurement, 783, 1685, 1719
multiple testing, 13, 511
replication probability, 875
type I, 55
Errors-in-variables
risk factors, 783
Essence design matrix
intentionally incomplete data, 1889
Estimating equation
see also Generalized estimating equations
two-stage studies, 769
Estimation procedures
longitudinal data, 1929
Etiologic fraction *see* Attributable risk
Event probabilities
risk factor intervention trials, 1719
Event rate
logrank test, 1091
Exact unconditional tables
multinomial trials, 913
Exchangeable prior
relative risk estimation, 983
Expectation-Maximization algorithm
longitudinal data, 1809, 1861, 1929, 1981, 2033
non-randomly missing data, 799
repeated measures, 2039, 2111
Expected-Conditional Maximization
longitudinal data, 1809
Experimental designs
dose-response relationships, 685
Explanatory trials
missing data, 2043
Exponential model
gestational age, 1225
optimal checking procedures, 1343
sample size calculation, 179
Exposure
disease risk analysis, 1443, 2083
Extra-binomial variation
prevalence estimation, 1591
Eyes
visual field, 1131

F ratio
multiple comparisons, 863
Factorial analysis
interaction interpretation, 1403(L)
Factorial design
combination drugs, 1065
Falsificationism
clinical trials, 1263–1265(L)
Familial aggregation
minimum sample size, 1767
Fibonacci search scheme, 2063
Fieller's theorem
Bayesian methods, 1377
intermediate endpoint, 167
FISHER computer program, 2123
Fisher information matrix
outlier detection, 2133
Fisher's exact test
contingency tables, 845–847(L)
multinomial trials, 913
multiple test procedures, 511
Fixed dose trials
dose-response relationships, 685
Fixed effects
intentionally incomplete data, 1889
Flemming-Harrington-O'Brien test, 673
Flexibility
conditional probability stopping rule, 659
Foetal movement
cluster randomization, 307
Follow-up data
ommitted variable bias, 1195
Formulation effect
bioavailability/bioequivalence, 881
Forward selection, 2093
Frequency-matched case-control studies
control sample size, 1759
Frequentist growth curve analysis, 2001
Frequentist statistical method, 1, 23, 37, 875
Full span longitudinal design, 1889

Furosemide
bioequivalence, 1777

GAUSS computer package, 219, 1607, 1633
Gaussian random effects distribution, 1981
Gehan statistic, 1705
Gehan-Wilcoxon test, 193
Generalized bilinear model, 1225
Generalized EM, 1809
Generalized estimating equations
analysis of variance, 1033
correlated observations, 1503
longitudinal data, 1825, 2001
Generalized iterative Bayesian simulation, 1809
Generalized least squares
see also Least squares
distribution-free estimators, 1151
longitudinal data, 1861, 1929, 1967, 1981
omitted variable bias, 1195
repeated measures, 115
Generalized linear interactive modelling *see* GLIM
Generalized linear models
see also Linear models
longitudinal data, 1825, 1929
prevalence estimation, 1591
standardized parameters estimation, 559–560(L)
ventricular premature beats, 963
Generalized multivariate analysis of variance, 2031
Generalized rank-sum statistics, 491–509
Generalized signed rank test, 193
Generalized *t* statistics, 491–509
Genetic transmission
familial aggregation, 1767
Genstat computer package, 1425
Geographical coherence
measles morbidity, 1409
Geographical variation
relative risk estimation, 983
Gestational age
digit preference model, 1225
Gibbs sampler
disease risk analysis, 1443
longitudinal data, 1809, 1825, 2001
relative risk estimation, 983
GIBS *see* Generalized iterative Bayesian simulation
GLIM computer package
categorical data, 799
digit preference, 1225
generalized linear models, 923, 1591
latent class model, 2111
log-linear modelling, 101
platelet transfusions, 2123
Global test *see* Omnibus test
GMANOVA *see* Generalized multivariate analysis of variance
Gold standards
sensitivity/specificity, 1503
Gompertz distribution, 931
Graphical methods
cumulative hazard functions, 1465
disease risk analysis, 1443
longitudinal data, 2001
survival curves, 455
Group comparison
crude incidence curves, 813
Group randomized studies
correlated binomial variates, 1607
Group sequential data
Bayesian statistics, 23
early stopping rules, 673
interim analysis, 55
logrank procedure, 1359
sample size determination, 1391
study duration, 1477
Group testing
prevalence estimation, 1591
Growth curves
longitudinal data, 1955, 2001
random coefficient analysis, 243

Haemophiliacs
AIDS progression, 591
Haemostasis
registry, 345
Hamilton Rating Scale for Depression, 2043
Hausman test, 1195
Hazard models *see* Proportional hazards model
Hazard ratio
estimator comparison, 847–848(L)
mid-point imputation, 1569
Heart
rate/period variability, 125
Heart disease
see also Myocardial infarction
disease evolution/prevalence prediction, 295
event probabilities, 1719
follow-up data, 1195
intermediate endpoint validation, 167
longitudinal data, 1981
mortality prediction models, 475

Heart disease (*cont.*)
registries, 345
risk factors, 783
subjective rankings, 427
Hepatitis
cluster randomization, 307
Heterogeneity
dose-response relationships, 685
Heterogeneous diagonal parameter model, 101
Heterogeneous uniform association model, 101
Heterosexuals
drug users interaction, HIV risk, 1657
Hierarchical Bayes modelling, 2001
Hierarchical log-linear models, 799
Hierarchical normal model, 141
Hierarchical polynomial models, 703
Hinkley's method *see* V-mask
Hip prostheses loosening
crude incidence curves, 813
HIV (Human immunodeficiency virus)
AIDS onset, 591
doubly censored data, 1569
dynamic model, 1425
epidemic dynamics, 1657
prevalence estimation, 1633
registries, 345
stage-specific numbers, 831
time since exposure estimation, 939
Hodges-Lehmann location shift, 1151
Hodgkin's disease
geographical variation, 983
Homogeneity
adjusted attributable risk, 2083
distribution-free estimators, 1151
meta-analysis, 2077
small sample performance, 159
Hormone secretory pulses
outlier detection methods, 2133
Hospitals
patient classification, 1321
Human immunodeficiency virus *see* **HIV**
Humphrey perimeter, 1131
Hybrid epidemiologic design *see* Case-cohort
Hypergeometric model, 1533
Hypertension
24 hour blood pressure data, 1843, 2147
children at risk, 1187
cluster randomization, 307

ICM *see* Iterated conditional modes
Immediate response
sample size determination, 1391
Immune response
virus neutralization assays, 1253
Incidence
cancer, 1579
Incidence curves, 813
Incident cohort, 939
Income
nutrient intake consequences, 533
Incomplete adjustment
residual confounding, 1747
Incomplete data
see also Missing data
intentional, 1889
longitudinal, 1887–1963
multivariate, 1151
rate of change estimation, 621
serial multivariate data, 1041
Incubation distributions
AIDS incidence, 1633
Incubation period
doubly censored data, 1569
measles, 579
Independence model
multi-rater agreement, 101
Individual bioequivalence, 1777
Individual-level studies
biases, 1209
Infection curve, 1633
Infection time, 1569
Infectivity
sexually transmitted diseases, 565
Inference procedures
censored data, 1871
goodness of fit, 1511
Influence diagram
disease risk analysis, 1443
Information surface
combination drug trials, 1065
Informational complexity
psychotherapy, 231
Informative censoring
see also Right censoring
longitudinal data, 1861
rate of change estimation, 621
Injuries
severity/level, spinal cord, 1171
Integrated moving average
geographical coherence, 1409
Inter-observer agreement
Kappa statistic, 1511
Interaction
cummulative hazard functions, 1465
factorial analysis, 1403(L)

sexually transmitted diseases, 1533
Interim analysis
Bayesian analysis, 23, 37
clinical trials monitoring, 55
group sequential trials, 1485
sample size, 55, 1391
stopping rules, 659, 673
International Society for Clinical Biostatistics
International Meetings, 2041–2058
Intersection-union problems, 1057
Interval censoring
combined endpoints, 1705
Interval consensus
binary/interval ratings, 317
Intervention studies
event probabilities, 1719
intermediate endpoints, 167
Intraclass correlation
correlated binomial variates, 1607
Intracluster correlation
cluster number estimation, 751
familial aggregation, 1767
Intravenous drug users *see* Drug users
Inventory of Cancer Prevention Trials, 345
IPF *see* Iterative proportional fitting
Isotonic regression, 1171
Item non-response *see* Missing data
Iterated conditional modes, 1809
Iterative proportional fitting, 1809
Iterative simulation, 1809
Iteratively reweighted least squares, 1033, 1929

Jackknife
Cohen's kappa, 1530–1532(L)
mixed models, 2027
risk screening, 257
surveillance data aberrations, 1551
variance estimates, 101
Jenss negative exponential growth curve, 1929
Job-exposure matrices
disease risk analysis, 1443

k-ratio t tests
multiple comparisons, 863
Kalman filter recursive algorithm, 515
Kaplan-Meier survival analysis
AIDS progression, 591
cure-rate estimation, 931
discrete hazard estimation, 455
doubly censored data, 1569
follow-up times, 1527–1529(L)
Kappa statistic *see* Cohen's kappa
Kidney transplants
cummulative hazard functions, 1465
Kolmogorov-Smirnov statistic
area between curves, 1289
psychotherapy states, 231
Kuhn-Tucker conditions, 1633
Kullback-Leibler distance, 37, 1321
Kurtosis
data description, 333

L-moments, 333
Laboratory analyses
optimal checking procedures, 1343
Laird-Ware algorithm, 1981
Laplace approximation, 1377
Last case influence, 1615
Last observation carried forward, 2043
Latent class model, 2111
Latin squares
crossover studies, 560(L)
longitudinal data, 1967
simple carry-over model, 715
Lead levels
learning difficulties, 799
Learning difficulties
pre-natal blood lead levels, 799
Least squares regression
see also Generalized least squares
serial multivariate data, 1041
spinal cord injuries, 1171
Levelling
AIDS incidence estimation, 1633
Life tables
longitudinal data, 2029
regression models, 939
Likelihood ratio
generalized linear models, 923
odds ratio homogeneity tests, 159
risk screening, 257
Limited dilution cloning
subcloning, 132–133(L)
LINCS computer program, 1195
Linear covariance structure, 1889
Linear discriminant analysis, 1023
Linear minimum mean square error estimator, 621
Linear minimum variance unbiased estimator, 621
Linear models
see also Generalized linear models
longitudinal data, 1843, 1871
ommitted variable bias, 1195

Linear models (*cont.*)
random-effects, 1861
serial multi-site data, 1041
Linear regression
meta-analysis, 2077
missing data, 2043
non-nested models, 1321
ordered variables, 1023
random-effects model, 2039
repeated measures, 2123
risk factors, 783
Link functions
generalized linear models, 963
repeated measures, 1033
Lipid levels
longitudinal data, 2033
LISP-STAT computer package, 115, 939
LISREL computer package, 1195
LMS method
reference centile curves, 1305
Local unconditional variance
McNemar test, 1239
Locally-weighted running-line smoother, 1115
Log cumulative hazards, 1465
Log-linear models
longitudinal data, 1871
missing data, 643, 799
pairwise interobserver agreement, 101
Log-logistic distribution
stage-specific numbers, 831
Log-normal distribution
direct formulation effect, 881
longitudinal data, 1861
three-parameter, 897
Logarithmic transformation
bioavailability/bioequivalence studies, 881
Logistic regression
coefficient estimates, 953
collinearity diagnosis, 1273
confidence intervals computation, 923
continuous covariates, 1115
cross-validation performance, 475
disease risk analysis, 1443
event probabilities, 1719
longitudinal data, 1981
missing data, 2043
ordered variables, 1023
residual confounding, 1747
risk factors, 783
Logit model
Bayesian methods, 1377
maximum tolerated dose, 2063
Logrank test
doubly censored data, 1569
hazard ratio estimators, 847–848(L)
sample size, 179, 1091
study duration, 1477
Longitudinal data
see also Repeated measures
accelerated failure time model, 1871
analytical methods, 1809, 1825
blood pressure tracking correlations, 1187
crossover designs, 1967
drop-outs, 2043
EM algorithm extensions, 1809
generalized estimating equations, 1033
GMANOVA, 2031
hierarchical Bayes modelling, 2001
informative censoring, 1861
intentionally incomplete designs, 1889
mixed-model analysis, 2027
multivariate methods, 1915
non-linear models, 1929
plasma lipid levels, 2033
premature ventricular counts, 963
random effects models, 1981
rate of change estimation, 621
symposium, 1797–2040
systematic attrition, 2029
Lowess *see* Locally-weighted running-line smoother
Lung cancer
smoking effects, 141
Luteinizing hormone
pulsatile hormone time series, 2133

McNemar test
matched case-control studies, 1239
sample size, 1521
Malnutrition
nutritional anthropometry, 1289
Mann-Whitney difference
distribution-free estimators, 1151
Mantel-Haenszel statistic
attributable risk, 2083
discrete hazard estimation, 455
intermediate endpoint validation, 167
matched case-control data, 617
odds ratio homogeneity tests, 159
optimal sample size determination, 547
sample size requirements, 743
stratified case-cohort studies, 1599
stratified multistage surveys, 603

Marginal models
longitudinal data, 1825, 1981
Marginal probabilities
McNemar test, 1521
Marginal tables
multi-rater agreement, 101
Mark-recapture model
sexually transmitted diseases, 1533
Markov models
disease evolution, 295
longitudinal data, 1809, 1825
multiple reading procedures, 209
optimal checking procedures, 1343
psychotherapy states, 231
sample size calculation, 179
stage-specific numbers, 831
Marshall-Olkin models, 281
Matched case-control studies *see* Case-control studies
Matched data
table presentation, 617
Maximum plasma concentration
75/75 rule, 1333
Maximum tolerated dose
Bayesian methods, 1377
toxicity grades, 2063
MDI *see* Mental Development Index
Mean changes
repeated measures, 1685
Mean difference
distribution-free estimators, 1151
Mean response model, 2063
Measles
geographical coherence, 1409
incubation period analysis, 579
Measurement error
event probabilities, 1719
imprecision, 953
repeated measures, 1685
risk factors, 783
Mechanistic models
AIDS projections, 1425
Mental Development Index
low birth-weight enfants, 243
Meta-analysis
Bayesian analysis, 141
clinical trials registries, 345
odds ratio, 2077
Metastases
differential prognostic influence, 281
Midpoint imputation
doubly censored data, 1569
Midpoint method
McNemar test, 1521
Migraine
familial aggregation, 1767
MIN test
multiple comparisons, 1057
Minimum variance unbiased estimator, 881
Minitab computer package, 923
Misclassification
categorical data, 271–275(L)
ecologic study bias, 1209
gestational age, 1225
multiple group discrimination, 1623–1624(L)
Missing data
blood pressure measurements, 2147
categorical data, 799
closed-form estimates, 643
drop-outs, 2043
longitudinal studies, 1809, 1861, 1889, 1929
Misspecification
ecologic study bias, 1209
longitudinal data, 1929
residual confounding, 1747
Mitofsky-Waksberg method, 1009
Mixed models
longitudinal data, 1889, 2027
Mixed-effects non-linear models, 1929
Mixing pattern
HIV epidemic dynamics, 1657
Models
Bayesian, 37
continuous covariates, 1115
continuous time autoregressive, 515
correlated categorical data, 67
correlated multiple associations, 219
dose-response relationships, 685
dynamic error component, 533
HIV epidemic dynamics, 1657
meta analysis, 141
mortality prediction, 475
multi-rater agreement, 101
one-way nested, 633
parametric life table regression, 939
random effects, 579
repeated measures, 115
risk screening, 257
simple carry-over, 715
spinal cord injuries, 1171
Stage, 1633
Time-Since-Infection, 1633
Moment method
intraclass correlation, 1607

MONICA *see* Monitoring Trends & Determinants of Cardiovascular Disease
Monitoring
optimal checking procedures, 1343
Monitoring Trends and Determinants of Cardiovascular Disease (MONICA), 295
Monotonicity
cumulative sums, 1115
discriminant analysis, 1023
missing data, 2043
Monte Carlo simulations
censored paired data, 193
conditional probability stopping rule, 659
event probabilities, 1719
generalized t and rank-sum, 491
Kappa statistic, 1511
longitudinal data, 1809, 2001
meta-analysis, 141
multiple test procedures, 511
rare event clustering, 761
sample size determination, 1091
serial multivariate data, 1041
two-stage studies, 769
Most probable number adjustment, 1253
Moving interval average, 2147
Multi-grade toxicity scheme, 2063
Multi-rater agreement
categorical scale, 101
Multicentre studies
semiannual reports, 1367
serial multivariate data, 1041
stopping rules, 353
Multinomial sampling model, 2083
Multinomial studies
exact unconditional tables, 913
Multinomial unconditional variance
McNemar test, 1239
Multiple associations
semi-Bayes approach, 219
Multiple comparisons
drugs/controls, 1057
k-ratio t tests, 863
Multiple endpoints
subjective rankings, 427–454
Multiple group discrimination
misclassification, 1623–1624(L)
Multiple imputation
longitudinal data, 1809
time since exposure, 939
Multiple pool sizes, 1591
Multiple ratings, 317
Multiple reading procedures, 209
Multiple testing
Bayesian subset analysis, 13
discrete data, 511
Multivariate growth curve *see* Generalized multivariate analysis of variance
Multivariate methods
clustered binary data, 1915
drug safety, 1075
incomplete data, 1041, 1151
longitudinal data, 1887–1963, 2033
non-linear models, 1929
Myocardial infarction
see also Heart disease
beta-blockers effects, 141
disease prevalence, 295
survival predictors, 125
ventricular premature beats, 963

Nasopharyngeal carcinoma, 1759
Negative trinomial analysis, 307
Neural channel density theory, 1131
Neurological assessment
spinal cord injuries, 1171
Neurosurgery
registry, 345
Neutralizing activity
virus neutralization assays, 1253
New drug applications (NDA), 1075
Newton method, 923
Newton-Raphson method
cure rate estimation, 931
last case influence, 1615
latent class model, 2111
longitudinal data, 1915
maximum likelihoods, 115
toxicity grades, 2063
Non-linear data
longitudinal, 1887–1963
Non-nested regression models, 1321
Non-parametric methods
area between curves, 1289
cure-rates, censored survival data, 931
discriminant analysis, 1023
maximum likelihood estimators, 1981
Non-proportional hazards model, 179
Non-response, 1009
NONMEM computer program, 1777
North Central Cancer Treatment Group
cancer trial, 1–53
Nutrition
area between curves, 1289
variation between and within individuals, 533

O'Brien and Flemming
  sample size determination, 1391
  stopping rules, 23, 659, 673
Odds estimation
  bias, 953
Odds ratio
  homogeneity tests, 159
  McNemar test, 1521
  Mantel-Haenszel adjustment, 603
  meta-analysis, 2077
  multi-rater agreement, 101
  small sample performance, 159
Ommitted variable bias
  follow-up data, 1195
Omnibus test, 1151
Opthalmology
  computerized perimetry, 1131
Optimal checking procedures, 1343
Optimality
  statistical surveillance, 1489
  two-stage phase II designs, 853
Order statistics
  skewness and kurtosis, 333
Ordered variables
  discriminant analysis. 1023
Ordinal models
  classification error rates, 133–134(L)
Ordinary least squares
  see also Least squares
  carry-over model, 715
  cross-validation performance, 475
  longitudinal data, 1981, 2001
  omitted variable bias, 1195
  rate of change estimation, 621
Osteosarcoma
  distal femoral failure, 813
Outliers
  detection methods, 2133
  identification, 115
Overdispersion
  prevalence estimation, 1591

P-values
  replication, 875
Paired data
  censored, 193
Parallel plots
  repeated measures, 115
Parameterization
  polychotomous models, 557–559(L)
Partial likelihood
  last case influence, 1615
Partitioned ECM algorithm
  longitudinal data, 1809
Path specific survival, 455
Pearson chi-square
  multinomial trials, 913
  odds ratio homogeneity tests, 159
Pearson correlation
  geographical coherence, 1409
  sample size calculations, 1607
PECM *see* Partitioned ECM
Penalized likelihood
  maximization, 983
  reference centile curves, 1305
Percentage change
  baseline differences, 1624–1626(L)
Perimetry
  principal components analysis, 1131
Perinatal trials
  registry, 345
Person-intervals survival modelling, 1731
Person-years method, 1579
Peto method
  hazard ratio estimators, 847–848(L)
  meta-analysis, 141
Peto-Prentice-Wilcoxon test, 1871
Pharmacokinetics
  direct formulation effect, 881
  dose-response relationships, 685
  non-linear models, 1929
Pharmacology studies
  CORMS, 2037
Piecewise exponential model
  gestational age, 1225
  sample size determination, 1103
Piecewise linear distributions, 1103
Pike estimator, 847(L)
Placebo
  drug comparisons, 1057
Plasma lipid levels
  longitudinal data, 2033
Platelet transfusions
  efficacy factors, 2123
Pocock
  group sequential boundary, 23
  sample size determination, 1391
  stopping rules, 659, 673
Poisson model
  psychotherapy studies, 231
  residual confounding, 1747
Polychotomous models
  logistic regression, 1915
  parameterization, 557–559(L)

Pooled data
  prevalence estimation, 1591
Popperian philosophy, 1263–1265(L)
Population at risk, 1533
Population attributable risk *see* Attributable risk
Population averaged models
  categorical data, 67
  longitudinal data, 1825, 1929
Population bioequivalence, 1777
Post-treatment means
  repeated measures, 1685
Power computation
  generalized t and rank-sum statistics, 491
  intentionally incomplete data, 1889
  McNemar test, 1239
  repeated measures, 1685
Power curves
  sample size formulae, 1091
Pragmatic trials
  missing data, 2043
Pre-natal blood lead levels
  learning difficulties, 799
Prediction
  cross-validation performance, 475
  limits, AIDS projections, 1425
  short-term survival, 1731
Prefix method
  random digit dialling surveys, 1009
Pregnancy
  estimated gestational age, 1225
  tocolysis, 2077
Prentice-Wilcoxon test, 193
Presentation
  unmatched case-control data, 1789–1790(L)
Prevalence
  Bayesian methods, 1621–1622(L)
  cancer, 1579
  generalized linear models, 1591
Prevalent cohort
  time since exposure, 939
Prevention
  heart disease, 295
Primary biliary cirrhosis
  short term survival prediction, 1731
Principal components analysis, 1131
Proband studies, 1767
Probit model
  Bayesian methods, 1377
  longitudinal data, 1861
PROC IML computer package, 1151
Prognostic factors
  differential influence, 281
Projection
  AIDS cases, 1425
Propensity score
  clinical trial drop-outs, 2043
Prophylaxis
  measles incubation period, 579
Proportional hazards model
  see also Cox proportional...
  Bayesian statistics, 23
  cause-specific hazards, 813
  collinearity diagnosis, 1273
  cummulative hazard functions, 1465
  sample size, 179, 1103
  short-term survival prediction, 1731
  two-stage design, 5
Prospective studies
  sensitivity/specificity, 1503
Prostatectomy
  crude incidence curves, 813
Protein energy malnutrition, 1289
Protein intake
  variation, 533
Pseudo non-linear mixed-effects model, 1929
Pseudo-likelihood function
  two-stage studies, 769
Pseudo-maximum likelihood estimation, 1861
Psychoimmunologic studies
  repeated measures, 2035
Psychopharmacological research
  dose-response relationships, 685
Psychotherapy
  stochastic progression, 231
Public health surveillance
  correlated samples, 1551
Public health trials
  cluster randomization, 307
Pulsatile hormone time series
  outlier detection methods, 2133

Quality control
  optimal checking procedures, 1343
  statistical surveillance, 1489
Quality of life
  subjective rankings, 427–454

Radiotherapy
  breast cancer, crude incidence curves, 813
Random coefficient regression model, 1929
Random effects models
  incubation period analysis, 579
  linear regression lines, 2039
  longitudinal data, 1809, 1825, 1929, 1981, 2033

meta analysis, 141
Random-digit dialling surveys, 1009
Randomization
public health trials, 307
randomized blocks experiment, 863
randomized consent design, 131–132(L)
randomized parallel groups, drop-outs, 2043
stratified cluster designs, 743
Range of equivalence, 23
Rank tests
censored data, 193, 1871
Rank transform discrimination method, 1623–1624(L)
Rankings
subjective, 427–454
Rate of change
empirical Bayes inference, 621
Ratings consensus, 317
RDA *see* Recommended dietary allowance
Receiver-operating characteristic curve, 475
Recommended dietary allowance, 533
Recursive partitioning, 475
Recursive residuals
steady state departures, 515
Reed-Muench
virus neutralization assays, 1253
Reference centile curves
smoothing, 1305
Reference ranges
3-parameter log-normal distribution, 897
Registries
clinical trials directory, 345
Regression models
see also Generalized linear models
confidence intervals, 923
correlated categorical data, 67
residual confounding, 1747
survival analysis, 939
Regression to the mean
cross-over trials, 727
risk factors, 783, 1719
Relative odds estimation
bias, 953
Relative residual confounding, 1747
Relative risk
see also Attributable risk; Risk
Bayesian vs. empirical Bayes, 983
bioequivalence, 1777
collinearity diagnosis, 1273
last case influence, 1615
McNemar test, 1239
Reliability studies
Kappa statistic, 1511
Renal disease
diet effects, 1861
Renal transplants
rate of change estimation, 621
Repeated measures
see also Longitudinal data
analysis of variance, 1033
CORMS, 2037
crossover design, 1967
data analysis, 1843
day-to-day variance, 2035
hierarchical Bayes modelling, 2001
latent class model, 2111
linear regression lines, 2039
mean summary statistics, 1685
multivariate data, 1151
non-linear models, 1929
parallel plots, 115
platelet transfusions, 2123
rate of change estimation, 621
residual plots, 115
sample size, 633, 1391
short-term survival prediction, 1731
Replication
P-values, 875
Residual confounding, 1747
Residual plots, 115
Residuals
recursive, 515
Respiratory disease
smoking effects, 1915
Response
bias, surveys, 1009
dose relationship, 685, 703
profile, repeated measurements, 2111
Response surface methods, 1065
Restricted maximum likelihood
longitudinal data, 1889, 1929, 1967, 1981, 2001
Retrospective studies
sensitivity/specificity, 1503
Rhabdomyosarcoma
rare event clustering, 761
Rheumatoid arthritis
registry, 345
Right censoring
combined endpoints, 1705
rate of change estimation, 621
sequential logrank procedure, 1359
Risk
see also Relative risk; Attributable risk
adjusted attributable estimators, 2083
assessment, Bayesian methods, 1377

Risk (*cont.*)
cohort disease prevalence, 295
differential prognostic influence, 281
model-based screening, 257
ratio, stratified case-cohort studies, 1599
short-term survival prediction, 1731
Risk of disease
risk factor relationship, 783
Risk factors
control sample size, 1759
disease risk analysis, 1443
intervention trials, 1719
residual confounding, 1747
risk of disease relationship, 783
ROC ANALYZER computer package, 475
ROC curve *see* Receiver-operating characteristic curve
Runge-Kutta method, 1425, 1657

Safety data
multivariate approach, 1075
Sample size
cluster number estimation, 751
combination drug trials, 1065
confidence intervals, 269(L)
correlated binomial variates, 1607
crude estimation, 1099
familial aggregation, 1767
formulae comparison, 1091
group sequential trials, 1391
interim power evaluation, 55
Kappa statistic, 1511
Logrank test, 179
McNemar test, 1239, 1521
odds ratio homogeneity tests, 159
optimal determination, 547
proportional hazards survival studies, 1103
repeated measures, 633, 1685
strata-matched case-control studies, 1759
stratified cluster randomization, 743
SAS computer package, 101, 633, 685, 1981, 2147
CATMOD, 1843
DATA, 1533
GLM, 579, 1843
IML, 621, 1843, 1889, 2039, 2043
IML GEE, 963
LOGIST, 1719
NORMAL, 881
PC, 603
PHGLM, 281, 1731, 2093
PHREG, 1731
PROC CATMOD, 2063
PROC MATRIX, 2063
PROC REG, 2063
RANK, 1843
RANNOR, 1719
RANUNI, 1719
TTEST, 1843
Scan test
rare event clustering, 761
Score statistics
generalized linear models, 923
odds ratio homogeneity tests, 159
stepwise selection, 2093
Screening
model-based, 257
reference centile curves, 1305
Secant method
generalized linear models, 923
SECM *see* Supplemented ECM
Selenium levels
EAAS, 1343
optimal checking procedures, 1343
SEM *see* Supplemented EM
Semi-proportional hazards models
cumulative hazard functions, 1465
Sensitivity
correlated observations, 1503
drug trials, 1057
Sensitivity analysis
AIDS projections, 1425
Bayesian approach, 37
transmission probability estimation, 565
Sequential analysis
conditional probability stopping rule, 659
Sequential logrank procedure
withdrawal censoring, 1359
Serial biomarker data
autogregressive models, 515
Serial mulitvariate data
incomplete data, 1041
Seroconversion time
parametric estmates, 591
time since exposure, 939
Serum neutralizing activity
virus neutralization assays, 1253
Sexually transmitted diseases
mark-recapture model, 1533
transmission probability estimation, 565
Shannon entropy, 231
Shapiro-Francia test, 897, 1115
Shapiro-Wilk test, 881, 897
Shewhart test, 1489
Shewhart-Cusum scheme, 515

Shrinkage
  Bayesian analysis, 13
  risk screening, 257
Significant results
  replication, 875
Simulated annealing method, 1871
Simulations
  see also Monte Carlo simulations
  AIDS projections, 1425
  attributable risk, 2083
  clinical trials interim analysis, 55
  disease risk analysis, 1443
  outlier detection, 2133
  sample size calculation, 179
  toxicity grades, 2063
Single-step test
  multiple comparisons, 1057
Skewness
  data description, 333
Smoking
  birth weight, 643
  cancer risk, 141
  respiratory disease, 1915
Smoothing
  blood pressure profile, 2147
  covariance matrix, 1843
  reference centile curves, 1305
  relative risk estimation, 983
  scatterplots, 1115
Southwest Oncology Group
  Statisitcian's Report Worksheet, 1367
  two-stage designs, 853
Spanish Database of Clinical Trials, 345
Sparse data
  rare event clustering, 761
Spatial forecasting, 1409
Spearman-Brown formula
  z consensus ratings, 317
Spearman-Kärber
  spinal cord injuries, 1171
  virus neutralization assays, 1253
Specificity
  correlated observations, 1503
Spinal cord injuries
  severity/level estimation, 1171
Spline curves
  smoothing, 1305
Spline functions, 2147
Stability analysis
  Batch-to-batch variation, 269–270(L)
Stage model
  AIDS incubation distribution, 1633
Stage-specific numbers, 831
Staggered entry
  longitudinal data, 1861
Standard inflation factors
  collinearity diagnosis, 1273
Standardization
  ecologic study bias, 1209
Standardized mortality ratios
  relative risk estimation, 983
Standardized parameters
  estimation, 559–560(L)
Stata computer package, 475, 897, 1115
Statistical Analysis System *see* SAS
Statistician's Report Worksheet computer program, 1367
Steady states
  autoregressive models, 515
Stein's method, 55
Step functions, 23, 1023
Stepwise testing
  multiple comparisons, 1057
  selection methods, 2093
Stochastic curtailment, 23, 55
Stochastic processes
  disease prevalence prediction, 295
  distribution-free estimators, 1151
  psychotherapy studies, 231
  survival curve representation, 455
Stochastic relaxation
  see also Gibbs sampler
  longitudinal data, 2001
Stopping rules
  Bayesian, 23
  conditional probability, 659
  decision-theoretic evaluation, 673
  phase II trials, 853
  sequential, 1
Strata-matched case-control studies, 1759
Stratified data
  common risk ratio, 1599
  distribution-free estimators, 1151
  group sequential trials, 1477
  Mantel-Haenzsel adjustment, 603
  mark-recapture model, 1533
  sample size, 547, 743
  sexually transmitted diseases, 1533
Studentized residuals
  direct formulation effect, 881
Subject-specific model
  longitudinal data, 1929
Subset analysis
  Bayesian analysis, 13, 37
Sum rule
  HIV epidemic dynamics, 1657

Summary statistics, 1685
Supplemented ECM
  longitudinal data, 1809
Supplemented EM
  longitudinal data, 1809
Surveillance
  aberrations, 1551
  definition, AIDS, 1633
  HIV epidemic dynamics, 1657
  method evaluation, 1489
Surveys
  mark-recapture model, 1533
  response bias, 1009
Survival analysis
  accelerated failure time model, 1871
  AIDS, 591
  Bayesian analysis, 1–53
  bootstrap resampling, 2093
  cancer prevalence, 1579
  censored paired data, 193
  crude incidence curves, 813
  cure rate estimation, 931
  differential prognostic influence, 281
  expected survival, 1527–1530(L)
  gestational age, 1225
  graphical representation, 455
  last case influence, 1615
  logrank tests, 179
  longitudinal data, 1841–1885, 2029
  residual confounding, 1747
  sample size, 1103
  short-term survival, 1731
  study duration, 1477
  time since exposure, 939
  treatment comparison, 1103
  withdrawal censoring, 1359
Symposia
  Longitudinal Data Analysis, 1797–2040
  introduction, 1797
  keynote address, 1808
  overview, 1801
  poster session abstracts, 2025
  Session 1: clinical trials, survival analysis, 1841–1885
  Session 2: incomplete, multivariate, non-linear, 1887–1963
  Session 3: Bayes/Empirical Bayes, 1965–2023
  speakers and discussants, 1799
  tutorial, 1823
Systematic attrition
  longitudinal data, 2029
t-tests
  k-ratio, 863
Tables
  exact unconditional, 913
  matched case-control data, 617
Tag-recapture *see* Mark-recapture
Tail weight
  skewness and kurtosis, 333
Tarone risk ratio, 1599
Taylor series
  intermediate endpoint, 167
  Mantel-Haenszel adjustment, 603
  surveillance data aberrations, 1551
  transmission probabilities, 565
Telephone prefix method
  random-digit dialling surveys, 1009
Temporal variability
  event probabilities, 1719
Termination *see* Stopping rules
Test-to-reference formulation, 1333
Theophylline
  bioequivalence, 1777
Three-parameter log-normal distribution, 897
Thrombocytopenia
  platelet transfusions, 2123
Thrombosis
  registry, 345
Time dependent covariates, 455
Time effects
  repeated measures, 1843
Time series
  geographical coherence, 1409
  HIV epidemic dynamics, 1657
  outlier detection, 2133
  rare event clustering, 761
  statistical surveillance, 1489
  surveillance data aberrations, 1551
Time-dependent model, 1731
Time-since-exposure, 939
Time-Since-Infection model, 1633
Time-to-event measurements, 1705
Tocolysis
  preterm pregnancy, 2077
Toxicity
  Bayesian methods, 1377
  crude incidence curves, 813
  grades, 2063
Tracking
  correlation, 1187
  longitudinal data, 2027
Trajectories
  subjective ranking, 427–454

Transformation
bioavailability/bioequivalence studies, 881
descriptive statistics, 333
Transfusions
platelet, efficacy factors, 2123
Transition models, 1825
Transition probabilities, 295
Transitional models, 67
Transmission dynamics, 1657
Transmission probabilities, 565
Treatment
AIDS incubation effects, 1633
comparison, cummulative hazard functions, 1465
safety profile, 1075
Treatment effects
clinical trial drop-outs, 2043
combined endpoints, 1705
crossover designs, 1967
cumulative hazard functions, 1465
repeated measures, 1685, 1843, 2111
Trend test
meta-analysis, 2077
Tumours
biomarker data, 515
cancer prevalence, 1579
registry, 345
Two-stage studies
designs/analysis, 769

U statistic, 1705
Ultrasonographic data
serial multivariate data, 1041
Unadjusted approach
McNemar test, 1521
Unanimity rule, 209
Unbalanced data
cluster number estimation, 751
Unbalanced sample size allocation, 1091
Unconditional methods
McNemar test, 1239, 1521
multinomial trials, 913
Unequally timed visits
longitudinal data, 1861
Unit non-response *see* Missing data
Unit weight models
cross-validation performance, 475
Univariate analysis
longitudinal data, 1843
Unweighted least squares
see also Least squares
longitudinal data, 1861

Use function
sample size determination, 1391
study duration, 1477

V-mask
statistical surveillance, 1489
Vaccine trials
registry, 345
Validation
intermediate endpoints, 167
Variability
visual field, 1131
Variance component models
see also Random effects
categorical data, 67
measles incubation period, 579
Variance decomposition proportions, 1273
Variance estimation
correlated samples, 1551
Variation
among-class, 727, 751
between-patient, 533, 1321
within-class, 533, 727, 751, 1187
Ventricular dilation
angiotensin converting enzyme inhibition, 1705
Ventricular premature beats
myocardial infarction, 963
Virus challenge dose, 1253
Virus neutralization assays, 1253
Vision research
registry, 345
Visual field
principal components analysis, 1131

Wald statistic
backwards elimination, 2093
confidence intervals, 923
differential prognostic influence, 281
multi-rater agreement, 101
Washington-Baltimore HIV Research Directory, 345
Weibull distribution
AIDS incidence estimation, 1633
hazard rates, 37
seroconversion time, 591
stage-specific numbers, 831
time since exposure, 939
Weighted least squares
ANCOVA, 1843
interobserver agreement, 101
longitudinal data, 1861

Weighting analysis
  missing data, 2043
Wheelchair cushions
  pressure ulcers, 863
Wilcoxon rank-sum tests, 491, 1151
Williams square, 715
Winsorized delta method, 1551
Withdrawal censoring, 1359
Withdrawals *see* Missing data
Within-class variation
  BP tracking correlations, 1187
  cluster number estimation, 751
  cross-over trials, 727

Yates's correction, 845–847(L)

Z scores, 913, 1289
Zero skewness estimate, 897